EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy

David Dora, Syeda Mahak Zahra Bokhari iD, Kenan Aloss iD, Peter Takacs, Juliane Zsuzsanna Desnoix, György Szklenárik, Patrick Deniz Hurley, Zoltan Lohinai

International Journal of Molecular Sciences · 01.02.2023 · 24 (3) · 2769

DOI: 10.3390/ijms24032769 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.02.2023. Verfasst von David Dora und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, Histology, and Embryology, Semmelweis University, Tuzolto St. 58, 1094 Budapest, Hungary. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Gastrointestinal Microbiome, Neoplasms, Melanoma. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 240 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hungarian National Research, Development and Innovation Office, ÚNKP-22-5, New National Excellence Program of the Ministry for Culture and Innovation, Bolyai Fellowship of the Hungarian Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have changed how we think about tumor management. Combinations of anti-programmed death ligand-1 (PD-L1) immunotherapy have become the standard of care in many advanced-stage cancers, including as a first-line therapy. Aside from improved anti-tumor immunity, the mechanism of action of immune checkpoint inhibitors (ICIs) exposes a new toxicity profile known as immune-related adverse effects (irAEs). This novel toxicity can damage any organ, but the skin, digestive and endocrine systems are the most frequently afflicted. Most ICI-attributed toxicity symptoms are mild, but some are severe and necessitate multidisciplinary side effect management. Obtaining knowledge on the various forms of immune-related toxicities and swiftly changing treatment techniques to lower the probability of experiencing severe irAEs has become a priority in oncological care. In recent years, there has been a growing understanding of an intriguing link between the gut microbiome and ICI outcomes. Multiple studies have demonstrated a connection between microbial metagenomic and metatranscriptomic patterns and ICI efficacy in malignant melanoma, lung and colorectal cancer. The immunomodulatory effect of the gut microbiome can have a real effect on the biological background of irAEs as well. Furthermore, specific microbial signatures and metabolites might be associated with the onset and severity of toxicity symptoms. By identifying these biological factors, novel biomarkers can be used in clinical practice to predict and manage potential irAEs. This comprehensive review aims to summarize the clinical aspects and biological background of ICI-related irAEs and their potential association with the gut microbiome and metabolome. We aim to explore the current state of knowledge on the most important and reliable irAE-related biomarkers of microbial origin and discuss the intriguing connection between ICI efficacy and toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalGastrointestinal MicrobiomeNeoplasmsMelanomaDrug-Related Side Effects and Adverse ReactionsHumansImmune Checkpoint InhibitorsImmunotherapyBiomarkers

Stichwörter der Autor:innen

ICIanti-PD1 immunotherapygut microbiomeirAEsmetabolome

Substanzen

Antineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsBiomarkers

Autor:innen und Institutionen

  • Department of Anatomy, Histology, and Embryology, Semmelweis University, Tuzolto St. 58, 1094 Budapest, Hungary.
  • Translational Medicine Institute, Semmelweis University, 1094 Budapest, Hungary.
  • Department of Thoracic Surgery, Guy's Hospital, London SE1 9RT, UK.
  • National Korányi Institute of Pulmonology, Pihenő út 1-3, 1121 Budapest, Hungary.

ORCID-Profile: Syeda Mahak Zahra Bokhari, Kenan Aloss

Förderung

  • Hungarian National Research, Development and Innovation Office
  • ÚNKP-22-5, New National Excellence Program of the Ministry for Culture and Innovation
  • Bolyai Fellowship of the Hungarian Academy of Sciences

Zitieren

APA

Dora, D., Bokhari, S. M. Z., Aloss, K., Takacs, P., Desnoix, J. Z., Szklenárik, G., Hurley, P. D., & Lohinai, Z. (2023). Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy. International Journal of Molecular Sciences, 24(3), 2769. https://doi.org/10.3390/ijms24032769

Vancouver

Dora D, Bokhari SMZ, Aloss K, Takacs P, Desnoix JZ, Szklenárik G, et al. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy. International Journal of Molecular Sciences. 2023;24(3):2769. doi:10.3390/ijms24032769

BibTeX
@article{Dora2023,
  author = {Dora, David and Bokhari, Syeda Mahak Zahra and Aloss, Kenan and Takacs, Peter and Desnoix, Juliane Zsuzsanna and Szklenárik, György and Hurley, Patrick Deniz and Lohinai, Zoltan},
  title = {Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {3},
  pages = {2769},
  doi = {10.3390/ijms24032769}
}
Kostenlos starten →